Huttig Building Products, Inc. HBP
10.70 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
10.68 Day range 10.70
52-week range unavailable
- Market cap
- 292.40M
- Forward P/E
- 20.19
- Volume
- 304.28K
- Open
- 10.68
- Previous close
- 10.70
- Day's range
- 10.68 – 10.70
- Earnings date
- May 2, 2022
1M +0.03 (+0.28%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 10.14
- 200-day average
- 8.35
Analyst view
Price target (mean) —
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
May 2, 2022
Expected May 2, 2022. Consensus EPS estimate 0.00.
Financials — quick view
HBP Revenue — quarterly 272.70M
HBP Net income — quarterly 15.50M
HBP EPS — quarterly 0.56
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 2, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 2, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 3, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Jul 28, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 3, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Mar 1, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2017 | Singular Research | init | — | Buy |
News
Helix BioPharma (TSE:HBP) Reaches New 12-Month Low – Here’s What Happened 
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development 
Helix Biopharma Corp. Announces Board Composition Changes 
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development 
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026 
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures 
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options 
Helix BioPharma (TSE:HBP) Stock Passes Above Fifty Day Moving Average – Should You Sell? 
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026 
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Your note
Sign in to keep a note on HBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FURIO ROBERT | Chief Operating Officer | Stock Award(Grant) | Jan 25, 2021 | 324,047 |
| GLASS DONALD L | Director | Stock Award(Grant) | Jan 25, 2021 | 204,570 |
| HIBBERD JAMES F | Director | Stock Award(Grant) | Jan 25, 2021 | 85,697 |
| HOAGLAND GINA GALGANO | Director | Stock Award(Grant) | Jan 25, 2021 | 70,099 |
| KEIPP PHILIP W | Chief Financial Officer | Stock Award(Grant) | Jan 25, 2021 | 287,930 |
| LARMON PATRICK L | Director | Stock Award(Grant) | Jan 25, 2021 | 87,095 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna Fundamental Investments, LLC | 0.11% | 29,483 | 315.47K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.20% | 600,943 | 6.43M | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 1.07% | 292,514 | 3.13M | Mar 30, 2022 |
| DFA U.S. Small Cap Series | 0.82% | 224,969 | 2.41M | Apr 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 0.54% | 146,853 | 1.57M | Apr 29, 2022 |
| Fidelity Extended Market Index Fund | 0.40% | 110,658 | 1.18M | Apr 29, 2022 |
| Highland Fds I-NexPoint Merger Arbitrage Fund | 0.35% | 96,889 | 1.04M | Mar 30, 2022 |